Lyra Therapeutics, Inc. LYRA
We take great care to ensure that the data presented and summarized in this overview for Lyra Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LYRA
View all-
Perceptive Advisors LLC New York, NY12.8MShares$3.44 Million0.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.77MShares$1.29 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$764,0940.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$750,6700.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$467,3470.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.06MShares$285,3430.12% of portfolio
-
Acadian Asset Management LLC Boston, MA986KShares$266,1200.0% of portfolio
-
Morgan Stanley New York, NY812KShares$219,1710.0% of portfolio
-
Geode Capital Management, LLC Boston, MA755KShares$203,8750.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny682KShares$184,0320.0% of portfolio
Latest Institutional Activity in LYRA
Top Purchases
Top Sells
About LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Insider Transactions at LYRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Harlan Waksal Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
275,000
+33.87%
|
-
|
|
Nov 10
2023
|
Harlan Waksal Executive Chair |
BUY
Open market or private purchase
|
Direct |
25,000
+8.71%
|
$50,000
$2.96 P/Share
|
|
May 31
2023
|
Nbvm Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,805,416
+20.88%
|
$3,610,832
$2.43 P/Share
|
|
May 31
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
3,610,832
+23.94%
|
$7,221,664
$2.49 P/Share
|
|
May 31
2023
|
Edward T Anderson |
BUY
Open market or private purchase
|
Indirect |
1,805,416
+20.88%
|
$3,610,832
$2.43 P/Share
|
|
Jan 31
2023
|
Robert E. Richard SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 31
2023
|
Corinne Noyes Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+50.0%
|
-
|
|
Jun 10
2022
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
4,000
+26.1%
|
$20,000
$5.05 P/Share
|
|
May 16
2022
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
328
+4.28%
|
$1,640
$5.0 P/Share
|
|
May 13
2022
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
3,500
+33.33%
|
$14,000
$4.81 P/Share
|
|
Apr 12
2022
|
Edward T Anderson |
BUY
Open market or private purchase
|
Direct |
118,483
+50.0%
|
$473,932
$4.22 P/Share
|
|
Apr 12
2022
|
Edward T Anderson |
BUY
Open market or private purchase
|
Indirect |
2,369,667
+36.72%
|
$9,478,668
$4.22 P/Share
|
|
Apr 12
2022
|
Nbvm Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,369,667
+36.72%
|
$9,478,668
$4.22 P/Share
|
|
Apr 12
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
5,924,170
+42.98%
|
$23,696,680
$4.22 P/Share
|
|
Apr 12
2022
|
Harlan Waksal Executive Chair |
BUY
Open market or private purchase
|
Direct |
236,966
+50.0%
|
$947,864
$4.22 P/Share
|
|
Jun 17
2021
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
3,500
+50.0%
|
$28,000
$8.97 P/Share
|
|
Dec 16
2020
|
Nancy Lynn Md Snyderman |
BUY
Open market or private purchase
|
Direct |
1,025
+50.0%
|
$9,225
$9.72 P/Share
|
|
May 05
2020
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
625,000
+24.42%
|
$10,000,000
$16.0 P/Share
|
|
May 05
2020
|
Perceptive Advisors LLC Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
259,346
-8.97%
|
$4,149,536
$16.0 P/Share
|
|
May 05
2020
|
Perceptive Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
480,825
+14.0%
|
$3,846,600
$8.63 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 275K shares |
|---|---|
| Open market or private purchase | 25K shares |